Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Baiyunshan Pharma Raises $1.6 Billion in Secondary Offering

publication date: Jan 13, 2015
Guangzhou Baiyunshan Pharmaceutical Holdings will raise $1.6 billion in a secondary offering, which it will use for various corporate initiatives, including expanding its China's online drug selling effort. One of the investors is Yunfeng, the private equity firm co-founded by Jack Ma, CEO of China's huge Alibaba online marketplace. Mr. Ma's participation attracted a great deal of media attention, even though Yunfeng is buying only one-twentieth of the total offering. Baiyunshan is the first manufacturer of generic Viagra in China. More details....

Stock Symbols: (HK: 874) (NYSE: BABA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital